You are here:

Adefovir dipivoxil (Hepsera®)


Following a full resubmission

Adefovir dipivoxil (Hepsera) is accepted for restricted use within NHS Scotland for the treatment of chronic hepatitis B in adults with either compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis, or decompensated liver disease. Its use is restricted to patients who demonstrate lamivudine resistance.

Drug Details

Drug Name: Adefovir dipivoxil (Hepsera®)
SMC Drug ID: 54/03
Manufacturer: Gilead Sciences Ltd
Indication: Chronic hepatitis B
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 9 May 2005

Archived Advice

Full submission 11 August 2003